Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer

Lung Cancer

Volumn 104, Issue , 2017, Pages 111-118

  Kato, Terufumi ^a   Masuda, Noriyuki ^b   Nakanishi, Yoichi ^c   Takahashi, Masashi ^d   Hida, Toyoaki ^e   Sakai, Hiroshi ^f   Atagi, Shinji ^g   Fujita, Shiro ^h   Tanaka, Hiroshi ⁱ   Takeda, Koji ^j   Satouchi, Miyako ^k   Namba, Yoshinobu ^l   Tamura, Tomohide ^m  

^a KANAGAWA CANCER CENTER   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d Yujin Yamazaki Hospital   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^h INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

^j OSAKA CITY GENERAL HOSPITAL   (Japan)

^k HYOGO CANCER CENTER   (Japan)

^l ONO PHARMACEUTICAL CO   (Japan)

^m ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Chest image; Drug induced lung injury; Interstitial lung disease; Nivolumab; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; METHYLPREDNISOLONE; MOTESANIB; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; STEROID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID; TUBULIN MODULATOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHIECTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPANESE (PEOPLE); LUNG INJURY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; ORGANIZING PNEUMONIA; OXYGEN DESATURATION; OXYGEN THERAPY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION PNEUMONIA; RECURRENT DISEASE; RESPIRATORY FAILURE; SMOKING; TREATMENT DURATION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; EPIDEMIOLOGY; FEMALE; JAPAN; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; SMOKING; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED; TUBULIN MODULATORS;

EID: 85007494884     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.12.016     Document Type: Article

References (11)

1. [1] Saito, Y., Gemma, A., Current status of DILD in molecular targeted therapies. Int. J. Clin. Oncol. 17 (2012), 534–541.
2. [2] Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
3. [3] Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
4. [4] Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
5. [5] ONO Pharmaceutical. A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent squamous NSCLC [JapicCTI-132072]. Available at URL: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132072 (Accessed 21 July 2016).
6. [6] ONO Pharmaceutical. A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent non-squamous NSCLC [JapicCTI-132073]. Available at URL: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132073 (Accessed 21 July 2016).
7. [7] Kudoh, S., Kato, H., Nishiwaki, Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177 (2008), 1348–1357.
8. [8] Kubota, K., Nishiwaki, Y., Tamura, T., et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J. Thorac. Oncol. 3 (2008), 1439–1445.
9. [9] Endo, M., Johkoh, T., Kimura, K., Yamamoto, N., Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52 (2006), 135–140.
10. [10] Ando, M., Okamoto, I., Yamamoto, N., et al. Predictive factors for interstitial lung disease antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 24 (2006), 2549–2556.
11. [11] Koyama, S., Omura, T., Yonezawa, A., et al. Gefitinib and erlotinib lead to phosphorylation of eukaryotic initiation factor 2 alpha independent of epidermal growth factor receptor in A549 cells. PLoS One, 10, 2015, e0136176.